ITMI20132087A1 - DIETARY SUPPLEMENT - Google Patents
DIETARY SUPPLEMENTInfo
- Publication number
- ITMI20132087A1 ITMI20132087A1 IT002087A ITMI20132087A ITMI20132087A1 IT MI20132087 A1 ITMI20132087 A1 IT MI20132087A1 IT 002087 A IT002087 A IT 002087A IT MI20132087 A ITMI20132087 A IT MI20132087A IT MI20132087 A1 ITMI20132087 A1 IT MI20132087A1
- Authority
- IT
- Italy
- Prior art keywords
- weight
- food supplement
- supplement according
- sodium
- infections
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 16
- 229960004308 acetylcysteine Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000013589 supplement Substances 0.000 claims description 14
- 244000131360 Morinda citrifolia Species 0.000 claims description 13
- 235000008898 Morinda citrifolia Nutrition 0.000 claims description 13
- 235000017524 noni Nutrition 0.000 claims description 13
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 10
- 206010046914 Vaginal infection Diseases 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 201000008100 Vaginitis Diseases 0.000 claims description 7
- 230000002085 persistent effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 3
- 239000001099 ammonium carbonate Substances 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- RWYRUDPAALLKPX-UHFFFAOYSA-N 2,2-difluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)F RWYRUDPAALLKPX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001749 Calcium fumarate Substances 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001747 Potassium fumarate Substances 0.000 claims description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000001744 Sodium fumarate Substances 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 2
- 235000019296 calcium fumarate Nutrition 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 claims description 2
- SHPKCSFVQGSAJU-UAIGNFCESA-L dipotassium;(z)-but-2-enedioate Chemical compound [K+].[K+].[O-]C(=O)\C=C/C([O-])=O SHPKCSFVQGSAJU-UAIGNFCESA-L 0.000 claims description 2
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 2
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims description 2
- 239000002370 magnesium bicarbonate Substances 0.000 claims description 2
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 claims description 2
- 235000014824 magnesium bicarbonate Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- GCHCGDFZHOEXMP-UHFFFAOYSA-L potassium adipate Chemical compound [K+].[K+].[O-]C(=O)CCCCC([O-])=O GCHCGDFZHOEXMP-UHFFFAOYSA-L 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 235000011051 potassium adipate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- SHPKCSFVQGSAJU-SEPHDYHBSA-L potassium fumarate Chemical compound [K+].[K+].[O-]C(=O)\C=C\C([O-])=O SHPKCSFVQGSAJU-SEPHDYHBSA-L 0.000 claims description 2
- 235000019295 potassium fumarate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- KYKFCSHPTAVNJD-UHFFFAOYSA-L sodium adipate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCC([O-])=O KYKFCSHPTAVNJD-UHFFFAOYSA-L 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 235000011049 sodium adipate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000019294 sodium fumarate Nutrition 0.000 claims description 2
- 229940005573 sodium fumarate Drugs 0.000 claims description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 claims description 2
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 2
- 239000001393 triammonium citrate Substances 0.000 claims description 2
- 235000011046 triammonium citrate Nutrition 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 208000037009 Vaginitis bacterial Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- -1 rice starch Polymers 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- RAQQJEFTDXAGKW-UHFFFAOYSA-M C([O-])([O-])=O.[Mg+].[NH4+] Chemical compound C([O-])([O-])=O.[Mg+].[NH4+] RAQQJEFTDXAGKW-UHFFFAOYSA-M 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000203736 Mobiluncus Species 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 229940093922 gynecological antibiotic Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
Titolo: “Integratore alimentare” Title: "Food supplement"
Descrizione Description
La presente invenzione descrive un integratore alimentare che comprende: D-mannosio , Morinda citrifolia succo liofilizzato e N-Acetilcisteina (NAC). Forma un ulteriore aspetto della presente invenzione l’uso di detto integratore nella prevenzione e nel trattamento di infezioni e infiammazioni dell’apparato uro-genitale. Stato dell’arte The present invention describes a food supplement which comprises: D-mannose, Morinda citrifolia freeze-dried juice and N-Acetylcysteine (NAC). A further aspect of the present invention is the use of said supplement in the prevention and treatment of infections and inflammations of the uro-genital system. State of the art
La flora vaginale che si osserva in donne sane ostacola la colonizzazione della vagina da parte dei germi ostili. Questa importante funzione di difesa è attribuita alla capacità della flora batterica vaginale di occupare le possibili sedi di adesione degli altri microrganismi, sintetizzare perossido di idrogeno, avente azione battericida diretta ed indiretta, acidificare l'ambiente vaginale (pH 4-4,5). The vaginal flora that is observed in healthy women hinders the colonization of the vagina by hostile germs. This important defense function is attributed to the ability of the vaginal bacterial flora to occupy the possible adhesion sites of other microorganisms, synthesize hydrogen peroxide, having a direct and indirect bactericidal action, acidify the vaginal environment (pH 4-4.5).
Nel momento in cui si vengono a riscontrare carenze o alterazioni nella fisiologia della flora vaginale, si instaura una “flora vaginale anormale” alla quale si associano vaginosi specifiche, da Candida o da Trichomonas, vaginosi batteriche, caratterizzate da una eccessiva crescita di germi commensali quali Gardnerella vaginalis, Micoplasma hominis e di numerose specie di anaerobi quali Mobiluncus peptostreptococcus, Bacteroides, Eubacterium species, tutte a crescita sessile e/o vaginiti aerobiche, alla cui base vi è una diminuzione flora vaginale fisiologica seguita dall’aumento dei batteri aerobi di origine prevalentemente intestinale (Escherichia coli in primis, meno frequentemente Staphilococcus pyogenes, Pseudomonas, Proteus). When deficiencies or alterations in the physiology of the vaginal flora are found, an "abnormal vaginal flora" is established which is associated with specific vaginosis, from Candida or Trichomonas, bacterial vaginosis, characterized by an excessive growth of commensal germs such as Gardnerella vaginalis, Micoplasma hominis and numerous species of anaerobes such as Mobiluncus peptostreptococcus, Bacteroides, Eubacterium species, all with sessile growth and / or aerobic vaginitis, at the base of which there is a decrease in physiological vaginal flora followed by an increase in aerobic bacteria of predominantly origin intestinal (Escherichia coli in primis, less frequently Staphilococcus pyogenes, Pseudomonas, Proteus).
Studi recenti hanno fatto emergere che la vaginite aerobica insieme alla vaginosi batterica rappresentano circa il 70% di tutte le vaginiti ed inoltre che queste due forme patologiche possono coesistere. Recent studies have shown that aerobic vaginitis together with bacterial vaginosis represent about 70% of all vaginitis and also that these two pathological forms can coexist.
Secondo uno studio condotto dal Centers for Disease Control and Prevention (CDC) di Atlanta, fino all’80% delle infezioni batteriche che si riscontrano nei Paesi Occidentali sono da imputarsi a biofilm. I biofilm sono comunità strutturate di cellule batteriche spesso di specie diverse, anche fungine, racchiuse in una matrice polimerica autoprodotta e adesa ad una superficie inerte o vivente. Studi recenti hanno indagato sulla composizione e sulla organizzazione spaziale della componente microbica associata all’epitelio vaginale, arrivando a concludere che gli agenti patogeni associati a cistiti, vaginosi batteriche, vaginiti aerobiche e da Candida hanno la tendenza a formare biofilm. Questo massiccio ruolo dei biofilm in patologie vaginali è alla base dell’ assente o incompleta risposta agli antibiotici e agli antifungini e all’alta presenza di forme morbose recidivanti uro-ginecologiche antibiotico resistenti e tendenti alla cronicizzazione osservate. Alla presenza di biofilm conseguono una più lenta e ridotta penetrazione degli antibiotici; una più alta frequenza di coniugazione fra i batteri che promuove lo scambio di plasmidi contenenti geni codificanti per resistenze multiple agli antibiotici; l’insorgenza di fenotipi batterici resistenti agli antibiotici, per carenza di ossigeno e di nutrienti nelle zone più lontane dalla superficie del biofilm; un’attività antagonista di cataboliti microbici che interagendo con le molecole antibiotiche ne neutralizzano l’attività. Inoltre, il distacco di singoli batteri e aggregati (mono e multispecie) da un biofilm maturo funge da inoculo persistente promuovendo nell’organismo nuovi siti di colonizzazione e dando luogo alle cosiddette infezioni polimicrobiche antibiotico-resistenti a crescita sessile e tendenti alla cronicizzazione. Sono infatti sempre più numerose le segnalazioni di infezioni miste su biofilm polimicrobici, composti sia da specie batteriche aerobie e anaerobie che da specie fungine che creano notevoli problemi terapeutici. According to a study conducted by the Centers for Disease Control and Prevention (CDC) in Atlanta, up to 80% of bacterial infections found in Western countries are attributable to biofilms. Biofilms are structured communities of bacterial cells often of different species, including fungal ones, enclosed in a self-produced polymeric matrix and adhered to an inert or living surface. Recent studies have investigated the composition and spatial organization of the microbial component associated with the vaginal epithelium, concluding that the pathogens associated with cystitis, bacterial vaginosis, aerobic and Candida vaginitis have a tendency to form biofilms. This massive role of biofilms in vaginal pathologies is at the basis of the absent or incomplete response to antibiotics and antifungals and the high presence of morbid relapsing uro-gynecological antibiotic resistant and tending to chronic forms observed. The presence of biofilm results in a slower and reduced penetration of antibiotics; a higher frequency of conjugation among bacteria which promotes the exchange of plasmids containing genes coding for multiple antibiotic resistance; the onset of bacterial phenotypes resistant to antibiotics, due to lack of oxygen and nutrients in the areas farthest from the surface of the biofilm; an antagonistic activity of microbial catabolites which interacting with antibiotic molecules neutralize their activity. In addition, the detachment of single bacteria and aggregates (mono and multispecies) from a mature biofilm acts as a persistent inoculum promoting new colonization sites in the organism and giving rise to the so-called antibiotic-resistant polymicrobial infections with sessile growth and tending to become chronic. In fact, there are more and more reports of mixed infections on polymicrobial biofilms, composed of both aerobic and anaerobic bacterial species and fungal species that create significant therapeutic problems.
In genere le patologie sopra descritte vengono affrontate, senza ottenere risultati risolutivi, con un mix di terapie antibiotiche, debilitanti per il sistema immunitario, che arrivano col tempo a compromettere del tutto l'equilibrio della flora batterica vaginale, lasciando l'organismo del tutto privo di difese, esponendolo ad attacchi batterici di ogni tipo, e alla cronicizzazione delle stesse patologie. Inoltre le terapie antibiotiche creano ceppi di batteri mutanti antibiotico-resistenti, dando luogo ad un circolo vizioso che aggrava sempre più l’organismo sottoposto a tali trattamenti. In general, the pathologies described above are faced, without obtaining decisive results, with a mix of antibiotic therapies, debilitating for the immune system, which over time come to completely compromise the balance of the vaginal bacterial flora, leaving the body completely devoid of defenses, exposing it to bacterial attacks of all kinds, and to the chronicization of the same pathologies. In addition, antibiotic therapies create strains of antibiotic-resistant mutant bacteria, giving rise to a vicious circle that increasingly aggravates the organism subjected to such treatments.
In particolare l'Italia è stata segnalata dall'Unione Europea per abuso di prescrizione di antibiotici, in particolar modo nella gestione delle infezioni all'apparato urinario. In particular, Italy has been reported by the European Union for abuse of antibiotic prescriptions, especially in the management of urinary tract infections.
Per superare le problematiche sopra illustrate, é fortemente avvertita l’esigenza di una composizione formulata in maniera tale da essere somministrabile per via orale con elevata compliance del paziente, capace di prevenire e trattare infezioni acute e croniche vaginali sostenute da biofilm. To overcome the problems described above, the need is strongly felt for a composition formulated in such a way as to be administered orally with high patient compliance, capable of preventing and treating acute and chronic vaginal infections supported by biofilms.
Descrizione dell’invenzione Description of the invention
La presente invenzione descrive un integratore alimentare che comprende D-mannosio, Morinda citrifolia, N-Acetilcisteina (NAC). The present invention describes a food supplement which comprises D-mannose, Morinda citrifolia, N-Acetylcysteine (NAC).
In una ulteriore forma di realizzazione, detto integratore comprende altresì un regolatore di acidità. In una forma di realizzazione preferita, di detta Morinda citrifolia è presente il succo, preferibilmente liofilizzato. In a further embodiment, said integrator also comprises an acidity regulator. In a preferred embodiment, the juice, preferably freeze-dried, is present of said Morinda citrifolia.
L’integratore viene formulato in un modo convenzionale utilizzando uno o più veicolanti farmaceuticamente accettabili compresi eccipienti e veicolanti accettabili che facilitino la lavorazione dei composti attivi. The supplement is formulated in a conventional way using one or more pharmaceutically acceptable carriers including excipients and acceptable carriers that facilitate the processing of the active compounds.
L’integratore può essere formulato combinando i composti attivi con veicolanti farmaceuticamente accettabili ben noti nell’arte. Tali veicolanti permettono all’integratore della presente invenzione di venir formulato come compressa, pillola, polvere, granulo, confetto, capsula, liquido, gel, sciroppo, impasto, sospensione e simili, per l’ingestione orale da parte di un soggetto che ne necessiti. Sono preferiti la capsula, la compressa, la polvere il liquido, il liquido è particolarmente utile. Preparazioni per uso orale possono essere ottenute miscelando uno o più eccipienti con la composizione della presente invenzione, facoltativamente macinando la miscela risultante e lavorando la miscela di granuli, dopo l’aggiunta di ausiliari adatti, se si desidera, per ottenere compresse o nuclei per confetti. Eccipienti adatti possono essere riempitivi quali zuccheri, compresi fruttosio, lattosio, saccarosio, mannitolo e sorbitolo; e sostanze cellulosiche quali, per esempio, amido di mais, amido di grano, amido di riso, amido di patata, gelatina, gomma adragante, metilcellulosa, idrossipropilmetilcellulosa, carbossimetilcellulosa sodica e/o polivinilpirrolidone (PVP). Se si desidera, possono esservi aggiunti agenti disintegranti quali polivinilpirrolidone reticolato, agar, o acido alginico o un suo sale quale alginato di sodio, lubrificanti quali stearato di magnesio e veicolanti quali leganti. The integrator can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers allow the integrator of the present invention to be formulated as a tablet, pill, powder, granule, candy, capsule, liquid, gel, syrup, paste, suspension and the like, for oral ingestion by a person who needs it. . Capsule, tablet, powder, liquid are preferred, liquid is particularly useful. Preparations for oral use can be obtained by mixing one or more excipients with the composition of the present invention, optionally grinding the resulting mixture and working the mixture of granules, after the addition of suitable auxiliaries, if desired, to obtain tablets or cores for dragees. . Suitable excipients can be fillers such as sugars, including fructose, lactose, sucrose, mannitol and sorbitol; and cellulosic substances such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone (PVP). If desired, disintegrating agents such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate, lubricants such as magnesium stearate and carriers such as binders may be added.
Formulazioni per via orale possono includere capsule dure fatte di gelatina, così come capsule sigillate fatte di gelatina molle e di un plastificante, quale glicerolo o sorbitolo. Le capsule dure possono contenere la composizione della presente invenzione in miscela con riempitivi quali lattosio, leganti quali amidi, e/o lubrificanti quali talco o stearato di magnesio. Nelle capsule molli, i composti attivi possono essere disciolti o dispersi in solventi adatti, quali acido grasso, paraffina liquida, o glicoli polietilenici liquidi. Inoltre, possono anche essere aggiunti stabilizzanti. Oral formulations can include hard capsules made of gelatin, as well as sealed capsules made of soft gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules can contain the composition of the present invention in admixture with fillers such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate. In soft capsules, the active compounds can be dissolved or dispersed in suitable solvents, such as fatty acid, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers can also be added.
Si rivendica altresì l’uso di detto integratore e di formulazioni che lo comprendono per la prevenzione e il trattamento di infiammazioni e infezioni uroginecologiche. It also claims the use of said supplement and formulations that include it for the prevention and treatment of inflammation and urogynecological infections.
Composizioni adatte per l’uso qui rivendicato comprendono composizioni in cui i componenti attivi sono contenuti in una quantità efficace per raggiungere il loro scopo. Più specificamente, una quantità efficace significa una quantità della composizione efficace nel prevenire, alleviare o migliorare i sintomi della malattia. Compositions suitable for the use claimed herein include compositions in which the active components are contained in an effective amount to achieve their purpose. More specifically, an effective amount means an amount of the composition effective in preventing, relieving or improving the symptoms of the disease.
In una forma di realizzazione, l’integratore della presente invenzione comprende: In one embodiment, the integrator of the present invention comprises:
D-mannosio da 1 a 20% peso/peso D-mannose from 1 to 20% weight / weight
Morinda citrifolia succo liofilizzato da 0,1 a 10% peso/peso Morinda citrifolia freeze-dried juice from 0.1 to 10% weight / weight
N-Acetilcisteina (NAC) da 0,1 a 6% peso/peso N-Acetylcysteine (NAC) from 0.1 to 6% weight / weight
Preferibilmente, D-mannosio, Morinda citrifolia succo liofilizzato, NAC sono presenti in un rapporto in peso pari a 5 / 3 / 1. Preferably, D-mannose, Morinda citrifolia freeze-dried juice, NAC are present in a weight ratio equal to 5/3/1.
Più preferibilmente, detto integratore comprende: More preferably, said supplement comprises:
D-mannosio da 1,5 a 15%, o 2 – 12%, o 3 – 10% o 4 – 8% o 4,5 – 7% o circa 5% peso/peso; D-mannose from 1.5 to 15%, or 2 - 12%, or 3 - 10% or 4 - 8% or 4.5 - 7% or about 5% w / w;
Morinda citrifolia succo liofilizzato da 0,5 – 8%, 1 – 6%, 2 - 4% o circa 3% peso/peso Morinda citrifolia freeze-dried juice from 0.5 - 8%, 1 - 6%, 2 - 4% or about 3% weight / weight
NAC da 0,25 a 5%, o 0,5 – 4%, o 0,75 – 3%, o circa 1% peso/peso; NAC 0.25 to 5%, or 0.5 - 4%, or 0.75 - 3%, or about 1% w / w;
In una forma di realizzazione preferita, detto integratore comprende: In a preferred embodiment, said integrator comprises:
D-mannosio circa 5% peso/peso; D-mannose about 5% w / w;
Morinda citrifolia succo liofilizzato circa 3% peso/peso; Morinda citrifolia freeze-dried juice about 3% weight / weight;
N-Acetilcisteina circa 1% peso/peso. N-Acetylcysteine about 1% weight / weight.
In un’ulteriore forma di realizzazione, detto integratore comprende altresì un regolatore di acidità selezionato nel gruppo che comprende: maleati di sodio, maleato di potassio, maleati di calcio, adipato di sodio, adipato di potassio, fumarato di sodio, fumarato di potassio, fumarato di calcio, 1,4-eptonolattone, niacina, nicotinammide, citrato triammonico, ferrocitrato d'ammonio, carbonato di sodio, bicarbonato di sodio, carbonato di potassio, bicarbonato di potassio, carbonato d'ammonio, bicarbonato d'ammonio, carbonato di magnesio, bicarbonato di magnesio, glicerofosfato di sodio, glicerofosfato di calcio. Preferibilmente, detto regolatore di acidità è bicarbonato di sodio. In a further embodiment, said supplement also comprises an acidity regulator selected from the group which includes: sodium maleate, potassium maleate, calcium maleate, sodium adipate, potassium adipate, sodium fumarate, potassium fumarate, calcium fumarate, 1,4-eptonolactone, niacin, nicotinamide, triammonium citrate, ammonium ferrocitrate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, ammonium bicarbonate, ammonium carbonate magnesium, magnesium bicarbonate, sodium glycerophosphate, calcium glycerophosphate. Preferably, said acidity regulator is sodium bicarbonate.
Laddove l’integratore della presente invenzione è formulato in una formulazione liquida da somministrare per via orale, detti componenti sono diluiti in acqua depurata. Where the supplement of the present invention is formulated in a liquid formulation to be administered orally, said components are diluted in purified water.
Preferibilmente, detta formulazione liquida è dolcificata con l’aggiunta di un dolcificante naturale o di sintesi selezionato nel gruppo che comprende: melassa, succo di mela concentrato, succo di uva concentrato, stevioside, miele, sciroppo di riso, acero, sorgo, succo di agave, saccarosio, fruttosio, glucosio, sorbitolo, xilitolo, mannitolo, glicina, lattosio, monellina, eritritolo, acesulfame K, aspartame, saccarina, sucralosio, maltitolo, isomalto, ciclamato, neoesperidina diidrocalcone, naringina diidrocalcone. preferibilmente, detto dolcificante è fruttosio. Preferably, said liquid formulation is sweetened with the addition of a natural or synthetic sweetener selected from the group which includes: molasses, concentrated apple juice, concentrated grape juice, stevioside, honey, rice syrup, maple, sorghum, agave, sucrose, fructose, glucose, sorbitol, xylitol, mannitol, glycine, lactose, monellin, erythritol, acesulfame K, aspartame, saccharin, sucralose, maltitol, isomalt, cyclamate, neoesperidina dihydrocalcone, naringin dihydrocalcone. preferably, said sweetener is fructose.
L’integratore della presente invenzione, somministrato per via orale, si é sorprendentemente rilevato efficace nella prevenzione e nel trattamento di irritazioni e infezioni uro-ginecologiche. The supplement of the present invention, administered orally, has surprisingly been found to be effective in the prevention and treatment of uro-gynecological irritations and infections.
L’integratore della presente invenzione si é rivelato efficace nel proteggere e nel ripristinare la fisiologica flora vaginale. The supplement of the present invention has proved effective in protecting and restoring the physiological vaginal flora.
L’integratore della presente invenzione si è sorprendentemente rivelato in grado di bloccare l’adesione delle cellule batteriche sulla superficie epiteliale vaginale, prevenire la crescita microbica, inibire l’espansione dei patogeni e disgregare le matrici polisaccaridiche già formate del biofilm. L’integratore della presente invenzione si rivela pertanto utile nel trattamento e nella prevenzione delle recidive delle vaginosi specifiche, delle vaginosi batteriche e delle vaginiti aerobiche. The supplement of the present invention has surprisingly proved capable of blocking the adhesion of bacterial cells on the vaginal epithelial surface, preventing microbial growth, inhibiting the expansion of pathogens and disrupting the already formed polysaccharide matrices of the biofilm. The supplement of the present invention is therefore useful in the treatment and prevention of relapses of specific vaginosis, bacterial vaginosis and aerobic vaginitis.
In particolare, l’uso dell’integratore della presente invenzione si è dimostrato in grado di prevenire ed eliminare la co-aggregazione microbica, ostacolando lo scambio di informazioni intercellulari, di prevenire la formazione del biofilm di matrice polimerica prodotto da comunità strutturate di cellule batteriche e/o fungine (spesso di specie diverse), di agire sulle cosiddette cellule persistenti, contrastando le comunità batteriche intracellulari IBCs e le relative riserve intracellulari quiescenti insensibili agli antibiotici e alla normale risposta immunitaria. In particular, the use of the integrator of the present invention has been shown to be able to prevent and eliminate microbial co-aggregation, hindering the exchange of intercellular information, to prevent the formation of the polymeric matrix biofilm produced by structured communities of bacterial cells. and / or fungal (often of different species), to act on the so-called persistent cells, counteracting the IBCs intracellular bacterial communities and the related quiescent intracellular reserves insensitive to antibiotics and the normal immune response.
L’integratore della presente invenzione, prevenendo ed eliminando la co-aggregazione microbica, previene la formazione del biofilm o conduce alla disgregazione. I batteri, restando privi della difesa fornita dal biofilm, in presenza della composizione della presente invenzione perdono la loro capacità adesiva così che verranno eliminati tramite le urine. The integrator of the present invention, by preventing and eliminating microbial co-aggregation, prevents the formation of biofilm or leads to disintegration. The bacteria, remaining devoid of the defense provided by the biofilm, in the presence of the composition of the present invention lose their adhesive capacity so that they will be eliminated through the urine.
Con il termine “cellule persistenti” si intendono quelle cellule che sopravvivono ai trattamenti antimicrobici che uccidono la maggior parte delle cellule geneticamente identiche. Dette cellule sono infatti entrate in uno stato di crescita fisiologica estremamente lenta che li rende insensibili (refrattarie o tolleranti) all'azione dei farmaci antimicrobici. Quando queste cellule microbiche persistenti non vengono eliminate dal sistema immunitario, vanno a costituire un serbatoio da cui si svilupperà una recidiva dell'infezione, innescando così un ciclo di inoculazione persistente. The term "persistent cells" refers to those cells that survive antimicrobial treatments that kill most of the genetically identical cells. These cells have in fact entered a state of extremely slow physiological growth which makes them insensitive (refractory or tolerant) to the action of antimicrobial drugs. When these persistent microbial cells are not eliminated by the immune system, they form a reservoir from which a recurrence of the infection will develop, thus triggering a persistent inoculation cycle.
L’uso dell’integratore della presente invenzione si è dimostrato in grado anche di interrompere il ciclo di inoculazione persistente che causa nell’organismo nuovi siti di colonizzazione e dà luogo alle cosiddette infezioni polimicrobiche antibiotico-resistenti, tutte a crescita sessile e tendenti alla cronicizzazione. The use of the supplement of the present invention has also been shown to be able to interrupt the persistent inoculation cycle that causes new colonization sites in the organism and gives rise to the so-called antibiotic-resistant polymicrobial infections, all of which have sessile growth and tend to become chronic. .
L’integratore della presente invenzione ostacola l’aggressione di Candida Albicans, Escherichia Coli e altri batteri. The supplement of the present invention hinders the attack of Candida Albicans, Escherichia Coli and other bacteria.
I risultati sorprendenti ottenuti con l’utilizzo dell’integratore della presente invenzione sono resi possibili da una sinergia che si viene a creare fra D-mannosio, Morinda citrifolia e NAC e la risposta che gli stessi promuovono a contatto con gli organismi patogeni colonizzanti. The surprising results obtained with the use of the supplement of the present invention are made possible by a synergy that is created between D-mannose, Morinda citrifolia and NAC and the response that they promote in contact with colonizing pathogenic organisms.
In particolare, l’associazione di Morinda citrifolia, D-mannosio e NAC rende questa formulazione efficace e unica per la cura e la prevenzione delle recidive di tutti i tipi di vaginiti, delle cistiti da risalita, per la prevenzione delle malattie sessualmente trasmesse e delle complicanze di natura ostetrica. In particular, the association of Morinda citrifolia, D-mannose and NAC makes this formulation effective and unique for the treatment and prevention of relapses of all types of vaginitis, ascent cystitis, for the prevention of sexually transmitted diseases and complications of an obstetric nature.
L’integratore della presente invenzione permette di affrontare patologie dell'apparato urinario derivanti da infezioni microbiche, polimicrobiche e/o fungine, tendenti alla cronicizzazione, senza l'utilizzo di antibiotici, preservando funzionalità, salute, efficienza ed equilibrio dell'apparato urogenitale nella sua globalità. The integrator of the present invention allows to deal with urinary tract pathologies deriving from microbial, polymicrobial and / or fungal infections, tending to become chronic, without the use of antibiotics, preserving functionality, health, efficiency and balance of the urogenital system in its globality.
Claims (1)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002087A ITMI20132087A1 (en) | 2013-12-13 | 2013-12-13 | DIETARY SUPPLEMENT |
PCT/IB2014/066591 WO2015087213A1 (en) | 2013-12-13 | 2014-12-04 | Food supplement |
EP14830594.9A EP3079504A1 (en) | 2013-12-13 | 2014-12-04 | Food supplement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002087A ITMI20132087A1 (en) | 2013-12-13 | 2013-12-13 | DIETARY SUPPLEMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
ITMI20132087A1 true ITMI20132087A1 (en) | 2015-06-14 |
Family
ID=50115989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT002087A ITMI20132087A1 (en) | 2013-12-13 | 2013-12-13 | DIETARY SUPPLEMENT |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3079504A1 (en) |
IT (1) | ITMI20132087A1 (en) |
WO (1) | WO2015087213A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115634205B (en) * | 2022-11-18 | 2023-05-30 | 湖南九典制药股份有限公司 | Acetylcysteine particles and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060073156A1 (en) * | 2002-09-04 | 2006-04-06 | Zambon Group S.P.A. | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract |
US20060159788A1 (en) * | 2002-11-14 | 2006-07-20 | Brett West | Method and formulation for treating Candidiasis using Morinda citrifolia |
US20110064706A1 (en) * | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
-
2013
- 2013-12-13 IT IT002087A patent/ITMI20132087A1/en unknown
-
2014
- 2014-12-04 EP EP14830594.9A patent/EP3079504A1/en active Pending
- 2014-12-04 WO PCT/IB2014/066591 patent/WO2015087213A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060073156A1 (en) * | 2002-09-04 | 2006-04-06 | Zambon Group S.P.A. | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract |
US20060159788A1 (en) * | 2002-11-14 | 2006-07-20 | Brett West | Method and formulation for treating Candidiasis using Morinda citrifolia |
US20110064706A1 (en) * | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "Ausilium Lavanda", INTERNET CITATION, 22 March 2012 (2012-03-22), pages 1 - 2, XP002720395, Retrieved from the Internet <URL:http://web.archive.org/web/20120322111244/http://www.deakos.com/prodotto.php?tid=53> [retrieved on 20140217] * |
CESARE MARIA NAVA ET AL: "Trattamento e prevenzione delle recidive delle vaginiti", M.D. MEDICINAE DOCTOR, 15 June 2013 (2013-06-15), pages 26 - 29, XP055102517, Retrieved from the Internet <URL:http://www.passonieditore.it/md/08/Esperienze.pdf> [retrieved on 20140217] * |
Also Published As
Publication number | Publication date |
---|---|
EP3079504A1 (en) | 2016-10-19 |
WO2015087213A1 (en) | 2015-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2676168T3 (en) | Procedures to treat gastrointestinal diseases | |
CA2706709C (en) | Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms | |
JP2012520343A (en) | Combination therapy for the treatment of metabolic disorders | |
RU2008147269A (en) | APPLICATION OF ORGANIC COMPOUNDS | |
AU2017374015B2 (en) | Antibiotic compositions comprising silver and selenium | |
US20130046019A1 (en) | Methods of Treatment Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production | |
US11938123B2 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
EP1482919B1 (en) | Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes | |
ITMI20132087A1 (en) | DIETARY SUPPLEMENT | |
US6426369B1 (en) | Oxethazaine as antimicrobial agent | |
EP0707484A1 (en) | H 2? antagonist-alginate-antacid combinations | |
EP2329819B1 (en) | Pharmaceutical composition for use in treating sexually transmitted infections | |
CN105106147A (en) | Pemirolast potassium tablet and production technology thereof | |
CN112121105B (en) | Mouthwash spray for pets and preparation method thereof | |
US7811609B2 (en) | Use of metal compounds to treat gastrointestinal infections | |
CN101756924A (en) | Sustained-release tablets of faropenem sodium | |
US20150157653A1 (en) | Prevention of Clostridium Difficile Infection in High Risk Patients | |
US20170071887A1 (en) | Method for applying metformin and sodium butyrate in k-ras mutation cancer treatment | |
CN114557992B (en) | Application of compound pharmaceutical composition in preparation of medicine for treating interstitial pneumonia | |
US20230293507A1 (en) | Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer | |
Ruxer et al. | Fosfomycin and nitrofurantoin in the treatment of recurrent urinary tract infections in type 2 diabetic women: A preliminary report | |
Ruanguan et al. | Antibiotic therapy for typhoid fever | |
CN105878263A (en) | Medicine composition containing malic acid clebopride malate and application thereof | |
TWI672145B (en) | Use and pharmaceutical composition for metabolic disease prevention and/or treatment | |
CN116898862A (en) | Antibacterial composition, antibacterial drug and application |